Trophos Appoints Christine Placet as Chief Executive Officer
News Jun 14, 2012
Trophos SA has announced the appointment of Christine Placet as chief executive officer, effective immediately.
Christine was previously CFO of Trophos since 2004. Christine becomes CEO under a previously defined internal succession plan designed to provide continuity for Trophos. Trophos is financed to 2014.
Christine becomes CEO with a mandate to continue to bring the Trophos’ ongoing programs to a successful conclusion and to seek strategic partnerships for Trophos’ advance clinical development drug candidates:
• Olesoxime, which is in an ongoing pivotal trial in Spinal Muscular Atrophy (SMA) with results due in the second half of 2013
• Olesoxime for Multiple Sclerosis (MS) disease progression, a phase II proof-of-concept trial designed with global MS experts
• TRO40303, which is in an ongoing phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI), with results due before end 2012.
“The Trophos team has built a strong portfolio of advanced clinical drug candidates and I am delighted to be working with the Trophos management and its board to build further value in the next stage of its development,” said Christine Placet.
Placet continued, “There is considerable market potential of nearly USD two billion for the conditions targeted by our pipeline. As importantly, we will look to continue to bring hope to patients with the serious and under-treated conditions that we specialize in.”
“The board of Trophos is delighted to appoint Christine Placet as CEO,” said Marc Villecroze, chairman of the Trophos board.
Villecroze continued, “Christine has used her leadership and strategic skills in her eight years at Trophos that are necessary to deliver on Trophos’ ongoing programs and its strategic goals. We would like to record our sincere thanks to Damian Marron. He leaves Trophos in a strong position and with our very best wishes in his future career.”
Christine Placet has over 25 years' experience in a variety of areas of finance and business management.
Prior to joining Trophos as CFO in 2004, she was CFO in a number of growing companies and start-ups in various industries, and worked as an auditor for eight years for Ernst & Young.
She has a graduate diploma in financial accounting (DESCF) and a business school diploma from Sup de Co Marseille (DESCAF).
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE